TNF-α and IFN-γ are potential inducers of fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis

Journal of Investigative Dermatology

Volumn 133, Issue 2, 2013, Pages 489-498

  Viard Leveugle, Isabelle ^a,b   Gaide, Olivier ^b   Jankovic, Dragana ^c   Feldmeyer, Laurence ^c   Kerl, Katrin ^c   Pickard, Chris ^d   Roques, Stéphanie ^b   Friedmann, Peter S ^d   Contassot, Emmanuel ^c   French, Lars E ^c  

^a Saint Barthélémy   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; UPREGULATION;

EID: 84872597649     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.330     Document Type: Article

References (44)

1. Abe R, Shimizu T, Shibaki A et al. (2003) Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162:1515-20
2. Arany I, Brysk MM, Brysk H et al. (1996) Regulation of inducible nitric oxide synthase mRNA levels by differentiation and cytokines in human keratinocytes. Biochem Biophys Res Commun 220:618-22
3. Bruch-Gerharz D, Ruzicka T, Kolb-Bachofen V (1998) Nitric oxide in human skin: current status and future prospects. J Invest Dermatol 110:1-7
4. Caproni M, Antiga E, Parodi A et al. (2006) Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 154:1006-7
5. Chlichlia K, Peter ME, Rocha M et al. (1998) Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 91:4311-20
6. Chung WH, Hung SI, Hong HS et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486
7. Chung WH, Hung SI, Yang JY et al. (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14:1343-50
8. Correia O, Delgado L, Ramos JP et al. (1993) Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 129:466-8
9. French LE (2006) Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 55:9-16
10. Gandhi M, Kowal-Vern A, An G et al. (2008) Blister fluid composition in a pediatric patient with toxic epidermal necrolysis. J Burn Care Res 29: 671-5
11. Gilbert RS, Herschman HR (1993) "Macrophage" nitric oxide synthase is a glucocorticoid-inhibitable primary response gene in 3T3 cells. J Cell Physiol 157:128-32
12. Gubinelli E, Canzona F, Tonanzi T et al. (2009) Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 36:150-3
13. Heck DE, Laskin DL, Gardner CR et al. (1992) Epidermal growth factor suppresses nitric oxide and hydrogen peroxide production by keratino-cytes. Potential role for nitric oxide in the regulation of wound healing. J Biol Chem 267:21277-80
14. Hung SI, Chung WH, Liou LB et al. (2005) HLA-B&z.ast;5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102:4134-9
15. Hunger RE, Hunziker T, Buettiker U et al. (2005) Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116:923-4
16. Kim YM, Bombeck CA, Billiar TR (1999) Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 84:253-6
17. Lee SK, Kim HS, Lee HJ et al. (2006) Dual effect of nitric oxide in immortalized and malignant human oral keratinocytes: induction of apoptosis and differentiation. J Oral Pathol Med 35:352-60
18. Lerner LH, Qureshi AA, Reddy BV et al. (2000) Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 114:196-9
19. Limat A, Hunziker T, Boillat C et al. (1989) Post-mitotic human dermal fibroblasts efficiently support the growth of human follicular keratino-cytes. J Invest Dermatol 92:758-62
20. Marzano AV, Frezzolini A, Caproni M et al. (2007) Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immuno-pathol Pharmacol 20:557-66
21. Nassif A, Bensussan A, Boumsell L et al. (2004a) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114:1209-15
22. Nassif A, Moslehi H, Le Gouvello S et al. (2004b) Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 123: 850-5
23. Ormerod AD, Copeland P, Hay I et al. (1999) The inflammatory and cytotoxic effects of a nitric oxide releasing cream on normal skin. J Invest Dermatol 113:392-7
24. Paquet P, Jacob E, Damas P et al. (2002) Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability. Crit Care Med 30:2580-3
25. Paquet P, Jacob E, Damas P et al. (2005a) Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 297: 266-73
26. Paquet P, Jacob E, Pirson J et al. (2005b) Drug-induced toxic epidermal necrolysis and pancytopenia: a puzzling association. Int J Mol Med 16:29-33
27. Paquet P, Nikkels A, Arrese JE et al. (1994) Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 130:605-8
28. Paquet P, Pierard GE (2007) Glutathione-S-transferase pi expression in toxic epidermal necrolysis: a marker of putative oxidative stress in keratino-cytes. Skin Pharmacol Physiol 20:66-70
29. Park-Min KH, Serbina NV, Yang W et al. (2007) FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67-78
30. Pasutto F, Sticht H, Hammersen G et al. (2007) Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation. Am J Hum Genet 80:550-60
31. Paul C, Wolkenstein P, Adle H et al. (1996) Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134:710-4
32. Prins C, Vittorio C, Padilla RS et al. (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 207:96-9
33. Quaglino P, Caproni M, Antiga E et al. (2007) Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 214:296-304
34. Rhodes LE, Hashim IA, McLaughlin PJ et al. (1999) Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 79:288-90
35. Roujeau JC, Chosidow O, Saiag P et al. (1990a) Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23:1039-58
36. Roujeau JC, Guillaume JC, Fabre JP et al. (1990b) Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 126:37-42
37. Schneider P, Holler N, Bodmer JL et al. (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with down-regulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205-13
38. Shimizu Y, Sakai M, Umemura Y et al. (1997) Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratino-cytes. J Dermatol 24:80-7
39. Stur K, Karlhofer FM, Stingl G (2007) Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 127:802-7
40. Trent JT, Kirsner RS, Romanelli P et al. (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 139:39-43
41. Viard I, Wehrli P, Bullani R et al. (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobu-lin. Science 282:490-3
42. Viard-Leveugle I, Bullani RR, Meda P et al. (2003) Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 278:16183-8
43. Villada G, Roujeau JC, Clerici T et al. (1992) Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 128:50-3
44. Wojtkiewicz A, Wysocki M, Fortuna J et al. (2008) Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 88:420-1